Protonitazepyne
Appearance
![]() | |
Identifiers | |
---|---|
| |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C23H28N4O3 |
Molar mass | 408.502 g·mol−1 |
3D model (JSmol) | |
| |
|
Protonitazepyne (N-pyrrolidino protonitazene) is a benzimidazole derivative with opioid effects, which has been sold as a designer drug over the internet, first being mentioned in mid 2022 and definitively identified in drug seizures in Canada in early 2023 and Ireland in late 2023.[1] It is an analogue of etonitazene where the ethoxy group has been extended to propoxy, and the N,N-diethyl substitution has been cyclised into a pyrrolidine ring. While formal studies into its pharmacology have yet to be carried out, it is believed to be slightly less potent than the ethoxy analogue etonitazepyne but still a potent opioid.[2][3]
See also
[edit]- Isotonitazene
- Isotonitazepyne
- Metonitazene
- Etomethazene
- Etonitazepipne
- List of benzimidazole opioids
References
[edit]- ^ Killoran S, McNamara S, Kavanagh P, O'Brien J, Lakes R (May 2024). "Identification of N-pyrrolidino protonitazene in powders sold as heroin and associated with overdose clusters in Dublin and Cork, Ireland". Drug Testing and Analysis. doi:10.1002/dta.3707. PMID 38769669.
- ^ "Early signal alert: Emergence of online mentions of Protonitazepyne". National Drug Early Warning System. 29 July 2022.
- ^ "Analyzed Drug Report" (PDF). Drug Analysis Service and Cannabis Laboratories. Health Canada. April–June 2023.